ClinicalTrials.gg
Not yet recruitingNCT06603727Updated Sep 19, 2024

Computerized Cognitive Rehabilitation of Patients With Cognitive Deficits Due to the Human Immunodeficiency Virus

An interventional study of Computerized Gaming Rehabilitation Program 1 and Computerized Gaming Rehabilitation Program 2 in Human Immunodeficiency Virus and Cognitive Dysfunction, sponsored by Centre Hospitalier Universitaire Vaudois. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Primary conditionCognitive DysfunctionRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cognitive Dysfunction
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Cognitive Dysfunction.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire Vaudois · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.

Planned enrollment
40th of 48
24 · median 56
Started
2024
with 3 others
No phase
38 of 61
13 open now
Primary completion
2026-08
later than 5 of 20 live
Registered
49th of 61
by date

Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2024, is one of 38 with no phase, reaches primary completion later than 5 of the 20 other live ones, and was the 49th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cognitive Dysfunction with a site in Switzerland, or all of them as a file.
02

Study summary

WHO: 24 participants with cognitive deficits due to a Human Immunodeficiency Virus (HIV) infection, able to engage in moderate physical activity.

WHY: The Human Immunodeficiency Virus is known to cause deficits in cognitive function, even under effective pharmacological viral load suppression. Cognitive dysfunction in patients with HIV is frequent and has a detrimental impact on their everyday personal and professional life. The purpose of this study is to evaluate two sets of computerized exercises combining cognitive and physical effort to see if they can improve executive function in patients with an HIV infection.

WHAT: Study participants first undergo cognitive and physical assessments. Additional questionnaires will assess mood, everyday life cognition, function and quality. This will be followed by a 6 week training period with 2 training sessions a week. The effect of the physical and cognitive training will be measured in a post-training evaluation session. Six months after completion of the training, the study will evaluate cognitive and physical abilities of participants to study long-term effects of the respective training program.

WHERE: Both the evaluation and the training sessions will be conducted on the premises of the Lausanne University Hospital (Rue du Bugnon 46, 1005 Lausanne, Switzerland)

Read the detailed description

This is an exploratory Randomized Controlled Trial with the purpose of evaluating the potential of two sets of gamified cognitive and physical exercises in the neurorehabilitation of cognitive deficits due to an infection with the Human Immunodeficiency Virus (HIV).

Upon recruitment, eligible study participants (see 'Eligibility Criteria') receive a detailed oral and written description about the scientific background, aims and methods of the study. Additional information will be provided about potential benefits and risks associated with study participation, as well as about the voluntary nature of participation throughout the study. The participant's written informed consent is required for study enrollment.

After inclusion in the study, participants are randomized into one of two different training programs with equal chance of attribution and without possibility of choosing:

  • Program 1 involves brain training and guided, light physical exercise games on a tablet device. The exercise involves movements such as reaching, stepping, and stretching. Warm-up and cool down sessions are mandated prior to and following the tasks.
  • Program 2 involves gamified exercises displayed on a large screen. Participants use whole-body movements to complete the tasks. Tasks involve movements such as reaching, stepping, and jogging in place. These movements are tracked by a motion sensor. Warm-up and cool down sessions are mandated prior to and following the training sessions.

Independently of program attribution, participants engage in a pre-training assessment, a six-week training period, a post-training assessment and a 6-month-follow-up assessment.

Before the start of the training, participants are required to perform several cognitive and physical tests (including cyclo-ergospirometry) and fill out a number of questionnaires on subjective cognitive function, mood and quality of life. Additionally, an electroencephalography (EEG) will be performed to measure brain activity. The exercises, the questionnaires and the EEG serve as a baseline evaluation of cognitive, physical and neurophysiological function.

Following the first assessment, study participants engage in a six-week training period. In both programs, participants engage in two weekly trainings of ninety minutes duration each.

After completion of the training period, study participants engage in a post-training assessment to evaluate the effect of training on cognitive and physical performance. This session incorporates the same tasks and questionnaires as in the pre-training visit. An EEG will be used to characterize the training effects on dynamics of the underlying large-scale neuronal networks. The aim of the post-training assessment is to demonstrate immediate training effect of the two programs.

A final follow-up visit is scheduled 6 months after the completion of the last training session. The cognitive and physical testing together with the questionnaires and the EEG will be repeated to examine the long-term effects of the training programs.

03

Conditions studied

  • Human Immunodeficiency Virus
  • Cognitive Dysfunction

Keywords

  • HIV Infections
  • Communicable Diseases
  • Neurological Rehabilitation
  • Cognitive Behavioural Therapy
  • Exercise Therapy
  • Nervous System Diseases
  • Neurocognitive Disorders
  • Cognition Disorders
  • Mental Disorders
04

In context

Cognitive Dysfunction Reclassified

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

This study's planned enrollment of 24 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.

Compared within Cognitive Dysfunction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of an infection
  • Undetectable HIV load in the serum (\<50 copies/mL) over the last 6 months prior to study inclusion.
  • Z-score ≤ -1.0 in at least one of the three following tests:

    • Color Trail Test (CTT) Flexibility Index
    • subtest Code of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)
    • subtest Digit Span of the WAIS-IV
  • Z-score ≤ -1.0 in at least one of the following tests:

    • Symbol Digits Modalities Test (SDMT)
    • Brief Visuospatial Memory Test Revised (BVMT-R)
    • CTT Flexibility Index
    • Stroop Color-Word interference test

Exclusion criteria

Exclusion Criteria:

  • Clinically defined cause for cognitive deficits other than
  • Diagnosis of severe depression according to a cut-off score of ≥ 27 of the Center for epidemiological studies - depression questionnaire (CES-D; Metral et al., 2020; Radloff, 1977)
  • Diagnosis of HIV-associated dementia according to the Frascati Critera (Antinori et al., 2007)
  • Current psychotic symptoms according to the Mini-International Neuropsychiatric Interview (M.I.N.I. - L, Sheehan et al., 1998) subscale of psychotic symptoms
  • Antidepressive, anxiolytic or cART medication that has been changed over the last month
  • Thoracic pain and/or heart palpitations at rest, during or following a physical effort (based on self-report)
  • For patients without known and clinically stable cardio-vascular disease: abnormal rest readings suggestive of second degree type Mobitz or third degree atrioventricular blocking, pathological repolarization (T-wave inversion, ST elevation, abnormal lengthening in at least two corresponding leads), or typical features of channelopathies
  • Premature termination of maximal effort test due to cardiac problems
  • Falls in the past 12 weeks as evaluated in the enrolment interview (Hopkins Falls Grading Scale, Grade >1)
  • High risk of falling according a cutoff score > 15 sec in the Four Square Step Test (Dite \& Temple, 2002)
  • Incapacity to discriminate colors or insufficient visual acuity that cannot be corrected
  • Incapacity or unwillingness to provide
  • Insufficient knowledge of French to understand and follow instructions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Program 1

    Computerized Gaming Rehabilitation Program 1

    Device: Computerized Gaming Rehabilitation Program 1

  • Active comparator
    Program 2

    Computerized Gaming Rehabilitation Program 2

    Device: Computerized Gaming Rehabilitation Program 2

Interventions

  • DeviceComputerized Gaming Rehabilitation Program 1

    Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.

  • DeviceComputerized Gaming Rehabilitation Program 2

    Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.

07

What researchers measure

Primary outcomes

  1. Change in subjective everyday life cognition after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Subjective executive function is measured by the Working Memory Questionnaire (WMQ), a 30-item, self-administered scale (score range from 0 to 120), addressing working memory (10 items), attention (10 items) and general executive function (10 items). The higher the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  2. Change in speed of information processing after a 6 weeks period of gamified cognitive and physical training

    Measured by the Symbol Digit Modalities Test (SDMT), scored from 0 to 110. The lower the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  3. Change in cognitive flexibility after a 6 weeks period of cognitive and physical training (program 1 vs program 2)

    Measured by the time completion of the Color Trails Test (CTT) in CTT1 and CTT2 (i.e., Flexibility Index: (CTT2-CTT1)/CTT1). The higher the Flexibility Index, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  4. Change in visuospatial short-term memory after a 6 weeks period of cognitive and physical training (program 1 vs program 2)

    Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R), scored from 0 to 36. The lower the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in sustained attention after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Measured with the Test of Variables of Attention (TOVA) using the reaction time (RT) and the false alarm rate (FA). The higher the RT and FA, the more they reflect cognitive difficulties.

    Time frame: 6 weeks

  2. Change in cognitive interference after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Measured with the Denis-Kaplan Color-Word interference Stroop test using the time completion in each condition. The higher the time completion, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  3. Change in design fluency after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    The Five-Point Test will be used to assess design fluency using the total number of design produced. The lower the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  4. Change in cognitive flexibility after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    A subtest of a custom-made tablet-based cognitive evaluation tool will measure cognitive flexibility.

    Time frame: 6 weeks

  5. Change in visuo-spatial and verbal working memory control after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Measured using the Digit and Visuo-Spatial Span Test

    Time frame: 6 weeks

  6. Change in divided attention after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Measured using the Test of Attentional Performance subtest Divided Attention

    Time frame: 6 weeks

  7. Change in body composition (body fat and muscle mass) after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Body composition will be measured by bioelectrical impedance measure using the percentage of body fat and muscle mass.

    Time frame: 6 weeks

  8. Change in risk of falls after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Risk of falls will be assessed using the BTrackS Balance Plate (FDA registered class 1 medical device #3010668481).

    Time frame: 6 weeks

  9. Change in limits of postural stability after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Limits of postural will be assessed using the BTrackS Balance Plate (FDA registered class 1 medical device #3010668481).

    Time frame: 6 weeks

  10. Change in dynamic stability after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Dynamic stability will be assessed by the Four Square Step Test, which tests the participant's ability to step over objects forwards, sideways and backwards; the movements of the FSST are comparable to the ones implemented in the training program. The score is based on time taken to complete the test. The higher the score, the more it reflects balance difficulties.

    Time frame: 6 weeks

  11. Change in ability to perform a cognitive and physical dual task after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    In order to assess cognitive and motor dual task ability, the study participant will perform the Timed Up and Go Cognitive. The score is based on time taken to complete the test and errors or hesitations. The higher the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  12. Change in heart rate variability after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Heart rate and heart rate variability will be recorded at rest in supine position during a 5-minute window using a medical electrocardiogramm (ECG).

    Time frame: 6 weeks

  13. Change in systolic and diastolic blood pressure after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Determined by the mean of three blood pressure measurements using a sphygmomanometer and a stethoscope.

    Time frame: 6 weeks

  14. Change in anxiety after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Anxiety will be assessed using the State-Trait Anxiety Inventory (STAI; 20 items) in French, scored from 20 to 80. The higher the score, the higher the level of anxiety.

    Time frame: 6 weeks

  15. Change in mood after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Mood will be assessed using the Center for Epidemiologic Studies - Depression (CES-D; 20 items) in French, scored from 0 to 60. The higher the score, the higher the level of depression.

    Time frame: 6 weeks

  16. Change in everyday life activity / quality of life after a 6 weeks period of gamified cognitive and physical training

    Specifically developped for patients with an HIV infection, the Medical Outcomes Study HIV Health Survey (MOS-HIV; 35 items) will be used to assess everyday life activities and health-related quality of life. The score ranges from 0 to 100. The lower the score, the poorer the quality of life.

    Time frame: 6 weeks

  17. Change in everyday life cognition after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Everyday life cognition will be assessed using the Cognitive Failure Questionnaire (CFQ; 32 items). The score ranges from 0 to 128. The higher the score, the more it reflects cognitive difficulties.

    Time frame: 6 weeks

  18. Change in fatigue after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Study participants will rate their degree of physical, cognitive and psychosocial fatigue on the Modified Fatigue Impact Scale (MFIS; 21 items). The score ranges from 0 to 84. The higher the score, the greater the level of fatigue.

    Time frame: 6 weeks

  19. Change in apathy after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    Using the self-administred Dimensional Apathy Scale (DAS; 24 items), study participants will rate their degree of apathy. The score ranges from 0 to 96. The higher the score, the greater the level of apathy.

    Time frame: 6 weeks

  20. Change in alcohol and other substance consumption after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    The habits in the consumption of alcohol and other substances will be evaluated with an adapted version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST; 8 items; Khan et al, 2011).

    Time frame: 6 weeks

  21. Development of medication intake over the course of study participation.

    Participants' medication intake over the course of the study will be recorded in the register of an ongoing prospective, longitudinal and multicenter study, called the Neurocognitive Assessment in the Metabolic and Aging Cohort study (NAMACO).

    Time frame: 6 weeks

  22. Development of professional occupation/employment rate over the course of study participation.

    Participants' professional occupation/employment rate over the course of the study will be recorded in the register of an ongoing prospective, longitudinal and multicenter study, called the Neurocognitive Assessment in the Metabolic and Aging Cohort study (NAMACO). The employment rate will be measured in full-time equivalent, ranging from 0 to 100 %. The higher the employment rate, the better.

    Time frame: 6 weeks

  23. Development of self-reported activity profile over the course of study participation.

    Participants' self-reported activity profile over the course of the study will be recorded in the register of an ongoing prospective, longitudinal and multicenter study, called the Neurocognitive Assessment in the Metabolic and Aging Cohort study (NAMACO).

    Time frame: 6 weeks

  24. Change in the theta power frequency band over the frontal brain region (Anguera et al., 2022) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measured with an electroencephalogram (EEG) during the Test of Variable of Attention (TOVA).

    Time frame: 6 weeks

  25. Change in the latency of the P3b (Event-Related Potential; Anguera et al., 2013) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measured with an electroencephalogram (EEG) during the TOVA.

    Time frame: 6 weeks

  26. Change in the temporal dynamic of the resting brain activity (microstates analysis; Michel and Koenig, 2018; Spring et al, 2017) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measured with an electroencephalogram (EEG) during the resting state

    Time frame: 6 weeks

  27. Change in forced expiratory volume in one second (FEV1) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measured by a forced exhalation in the first second of a breath into a spirometer.

    Time frame: 6 weeks

  28. Change in maximal pulmonary capacity (measured in liters) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measured by a forced exhalation into a spirometer.

    Time frame: 6 weeks

  29. Change in peak oxygen capacity (VO2 peak) after a 6-week period of gamified cognitive and physical training (program 1 vs program 2)

    Measure using a standardized maximal effort test with incremental exercise on a cycling ergometer with gas exchange analyses.

    Time frame: 6 weeks

  30. Change in VO2 at anaerobic threshold after a 6 weeks period of gamified cognitive and physical training (program 1 vs program 2)

    VO2 at anaerobic threshold will be determined using a cyclo-ergospirometry.

    Time frame: 6 weeks

Other outcomes

  1. Subjective usability of the technology used in study.

    Regardless of training group attribution, study participants will rate the user-friendliness of the training using the 10-item System Usability Scale scored from 0 to 40. The higher the score, the better the utility.

    Time frame: 6 weeks

  2. Subjective experience with technology used in the study

    Regardless of training group attribution, study participants will rate the experience of the training using and the 4-item Perception of game training questionnaire scored from 10 to 50. The higher the score, the better the experience.

    Time frame: 6 weeks

  3. Perception of game training

    Regardless of training group attribution, study participants will rate their perception of game training using the Perception of game training questionnaire (4 statements on enjoyment, challenge, frustration and motivation associated with the game, participants rate their agreement with the statement on a Likert-scale from 1 (lowest) to 7 (highest)).

    Time frame: 6 weeks

08

Study locations

1 site
09

References and documents

Publications

  • Smith, A. (1982). Symbol digit modalities test (SDMT) manual (revised) Western psychological services. Los Angeles.
  • Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. J Int Neuropsychol Soc. 2004 Mar;10(2):301-3. doi: 10.1017/S1355617704102191. No abstract available. PubMed 15012851 ↗
  • Benedict, R. H. (1997). Brief Visuospatial Memory Test-Revised (BVMT-R). Odessa, FL: Psychological Assessment Resources. In: Inc
  • Vallat-Azouvi C, Pradat-Diehl P, Azouvi P. The Working Memory Questionnaire: a scale to assess everyday life problems related to deficits of working memory in brain injured patients. Neuropsychol Rehabil. 2012;22(4):634-49. doi: 10.1080/09602011.2012.681110. Epub 2012 Apr 27. PubMed 22537095 ↗
  • Brandt, J. (1991). The hopkins verbal learning test: Development of a new memory test with six equivalent forms. Clinical Neuropsychologist, 5(2), 125-142.
  • Rieu D, Bachoud-Levi AC, Laurent A, Jurion E, Dalla Barba G. [French adaptation of the Hopkins Verbal Learning Test]. Rev Neurol (Paris). 2006 Jun;162(6-7):721-8. doi: 10.1016/s0035-3787(06)75069-x. French. PubMed 16840980 ↗
  • Greenberg, L., Kindschi, C., & Corman, C. (1996). TOVA clinical guide. Los Alamitos, CA: Universal Attention Disorders.
  • Kollins SH, DeLoss DJ, Canadas E, Lutz J, Findling RL, Keefe RSE, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health. 2020 Apr;2(4):e168-e178. doi: 10.1016/S2589-7500(20)30017-0. Epub 2020 Feb 24. PubMed 33334505 ↗
  • Regard M, Strauss E, Knapp P. Children's production on verbal and non-verbal fluency tasks. Percept Mot Skills. 1982 Dec;55(3 Pt 1):839-44. doi: 10.2466/pms.1982.55.3.839. No abstract available. PubMed 7162920 ↗
  • Michel CM, Koenig T. EEG microstates as a tool for studying the temporal dynamics of whole-brain neuronal networks: A review. Neuroimage. 2018 Oct 15;180(Pt B):577-593. doi: 10.1016/j.neuroimage.2017.11.062. Epub 2017 Dec 2. PubMed 29196270 ↗
  • Spring JN, Tomescu MI, Barral J. A single-bout of Endurance Exercise Modulates EEG Microstates Temporal Features. Brain Topogr. 2017 Jul;30(4):461-472. doi: 10.1007/s10548-017-0570-2. Epub 2017 May 20. PubMed 28528447 ↗
  • Levett DZH, Jack S, Swart M, Carlisle J, Wilson J, Snowden C, Riley M, Danjoux G, Ward SA, Older P, Grocott MPW; Perioperative Exercise Testing and Training Society (POETTS). Perioperative cardiopulmonary exercise testing (CPET): consensus clinical guidelines on indications, organization, conduct, and physiological interpretation. Br J Anaesth. 2018 Mar;120(3):484-500. doi: 10.1016/j.bja.2017.10.020. Epub 2017 Nov 24. PubMed 29452805 ↗
  • Dite W, Temple VA. A clinical test of stepping and change of direction to identify multiple falling older adults. Arch Phys Med Rehabil. 2002 Nov;83(11):1566-71. doi: 10.1053/apmr.2002.35469. PubMed 12422327 ↗
  • Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther. 2000 Sep;80(9):896-903. PubMed 10960937 ↗
  • Radloff, L. S. (1977). The CES-D Scale:A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement, 1(3), 385-401.
  • Fuhrer, R. (1989). Fuhrer, R, Rouillon F. La version française de l'échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l'échelle d'autoévaluation Psychiatry and Psychobiology, 4, 163-166.
  • Spielberger, C. D. (1983). Manual for the State-Trait Anxiety Inventory STAI (form Y)(
  • Gauthier, J., & Bouchard, S. (1993). Adaptation canadienne-française de la forme révisée du State-Trait Anxiety Inventory de Spielberger. Canadian Journal of Behavioural Science/Revue canadienne des sciences du comportement, 25(4), 559.
  • Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997 Aug;6(6):481-93. doi: 10.1023/a:1018451930750. PubMed 9330549 ↗
  • Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982 Feb;21(1):1-16. doi: 10.1111/j.2044-8260.1982.tb01421.x. PubMed 7126941 ↗
  • Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Validity of a French version of the fatigue impact scale in multiple sclerosis. Mult Scler. 2007 Sep;13(8):1026-32. doi: 10.1177/1352458507077942. PubMed 17895294 ↗
  • Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994 Feb;21(1):9-14. PubMed 8180914 ↗
  • Radakovic R, Abrahams S. Developing a new apathy measurement scale: Dimensional Apathy Scale. Psychiatry Res. 2014 Nov 30;219(3):658-63. doi: 10.1016/j.psychres.2014.06.010. Epub 2014 Jun 19. PubMed 24972546 ↗
  • Khan R, Chatton A, Nallet A, Broers B, Thorens G, Achab-Arigo S, Poznyak V, Fleischmann A, Khazaal Y, Zullino D. Validation of the French version of the alcohol, smoking and substance involvement screening test (ASSIST). Eur Addict Res. 2011;17(4):190-7. doi: 10.1159/000326073. Epub 2011 Apr 14. PubMed 21494047 ↗
  • Metral M, Darling K, Locatelli I, Nadin I, Santos G, Brugger P, Kovari H, Cusini A, Gutbrod K, Tarr PE, Calmy A, Lecompte TD, Assal F, Monsch A, Kunze U, Stoeckle M, Schwind M, Schmid P, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M; NAMACO study group; Swiss HIV Cohort Study. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile. HIV Med. 2020 Jan;21(1):30-42. doi: 10.1111/hiv.12795. Epub 2019 Oct 7. PubMed 31589807 ↗
  • Brooke, J., SUS: A 'Quick and Dirty' Usability Scale. 1996.
  • Boot WR, Champion M, Blakely DP, Wright T, Souders DJ, Charness N. Video games as a means to reduce age-related cognitive decline: attitudes, compliance, and effectiveness. Front Psychol. 2013 Feb 1;4:31. doi: 10.3389/fpsyg.2013.00031. eCollection 2013. PubMed 23378841 ↗
  • Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. doi: 10.1212/01.WNL.0000287431.88658.8b. Epub 2007 Oct 3. PubMed 17914061 ↗
  • Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. PubMed 9881538 ↗
  • Maj M, D'Elia L, Satz P, Janssen R, Zaudig M, Uchiyama C, Starace F, Galderisi S, Chervinsky A; World Health Organization, Division of Mental Health/Global Programme on AIDS. Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol. 1993 Mar;8(2):123-35. PubMed 14589670 ↗
  • Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C; Composition of the ESPEN Working Group. Bioelectrical impedance analysis--part I: review of principles and methods. Clin Nutr. 2004 Oct;23(5):1226-43. doi: 10.1016/j.clnu.2004.06.004. PubMed 15380917 ↗
  • Sternberg S. High-speed scanning in human memory. Science. 1966 Aug 5;153(3736):652-4. doi: 10.1126/science.153.3736.652. PubMed 5939936 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Aug 2026, 22 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 22 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Sep 19, 2024
StartEst.
Oct 1, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06603727
Responsible party
Prof. Arseny Sokolov, MD, PhD (Professor, MD, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Sep 19, 2024
Start date
Oct 1, 2024 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Etienne Sallard, PhD
Contact
etienne.sallard@chuv.ch
+ 41 21 314 24 61
Arseny A. Sokolov, Prof MD PhD
Contact
arseny.sokolov@chuv.ch
+41 79 556 73 55
Arseny A. Sokolov, Prof MD PhD
principal investigator · Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Etienne Sallard, PhD
study chair · Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion